Here, we have demonstrated that the application of tipifarnib, one of the most potent farnesyl-transferase inhibitors results in synergistic anticancer effects in combination with KRAS G12D targeting pancreatic adenocarcinoma cells that have been shown to be therapy-resistant under 2D conditions. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.